Risk factors associated with the development of skin cancer after liver transplantation

Liver Transplantation

Volumn 8, Issue 10, 2002, Pages 939-944

  Mithoefer, Abigail B ^a   Supran, Stacey ^a   Freeman, Richard B ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RETINOID; STEROID; TACROLIMUS;

ADULT; AGE; ARTICLE; BASAL CELL CARCINOMA; BURN; CANCER INCIDENCE; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; EYE COLOR; FAMILY HISTORY; FEMALE; FOLLOW UP; HAIR COLOR; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MALE; MELANOMA; NEVUS; OCCUPATION; PREDICTION; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RECIPIENT; SEX DIFFERENCE; SKIN CARCINOGENESIS; SKIN CARCINOMA; SKIN COLOR; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; SUNBURN;

EID: 0036793230     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2002.35551     Document Type: Article

References (31)

1. Alam M, Ratner D. Cutaneous squamous cell carcinoma. N Eng J Med 2001;344:975-983.
2. Otley CC, Pittelkow MR. Skin cancer in liver transplant recipients. Liver Transplantation 2000;6:253-262.
3. Bouwes Bavinck JN, Hardie DR, Green A, Cutmore S, MacNaught A, O'Sullivan B, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. Transplantation 1996;61:715-721.
4. Levy M, Backman L, Husberg B, Goldstein R, McMillan R, Gibbs J, et al. De novo malignancy following liver transplantation: A single-center study. Transplant Proc 1993;25:1397-1399.
5. Jain AB, Yee LD, Nalesnik MA, Youk A, Marsh G, Reyes J, et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998;66:1193-1200.
6. Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, Geiran O, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999;40:177-186.
7. McCann J. Can skin cancers be minimized or prevented in organ transplant patients? J Nat Cancer Inst 1999;91:911-913.
8. DiGiovanna JJ. Posttransplantation skin cancer: Scope of the problem, management, and role for systemic retinoid chemoprevention. Transplant Proc 1998;30:2771-2775.
9. Tan-Shalaby J, Tempero M. Malignancies after liver transplantation: A comparative review. Sem Liver Dis 1995;15:156-164.
10. Penn I. The changing pattern of posttransplant malignancies. Transplant Proc 1991;23:1101-1103.
11. Euvard S, Kanitakis J, Pouteil-Noble C, Dureau G, Touraine JL, Faure M, et al. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatol 1995;33: 222-229.
12. Abel EA. Cutaneous manifestations of immunosuppression in organ transplant recipients. J Am Acad Dermatol 1989;21:167-179.
13. Sheil AGR, Disney APS, Mathew TH, Amiss N. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 1993;25:1383-1384.
14. Harden PN, Fryer AA, Reece S, Smith AG, Ramsay HM. Annual incidence and predicted risk of nonmelanoma skin cancer in renal transplant patients. Transplant Proc 2001;33:1302-1304.
15. Naldi L, Fortina AB, Lovati S, Barba A, Gotti E, Tessari G, et al. Risk of nonmelanoma skin cancer in italian organ transplant recipients. A registry-based study. Transplantation 2000;70: 1479-1484.
16. Ramsay HM, Fryer AA, Reece S, Smith AG, Harden PN. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am J Kidney Dis 2000;36:167-176.
17. Caforio ALP, Fortina AB, Piaserico S, Alaibac M, Tona F, Feltrin G, et al. Skin cancer in heart transplant recipients: Risk factor analysis and relevance of immunosuppressive therapy. Circulation 2000;102(suppl III):S222-S227.
18. Espana A, Martinez-Gonzalez A, Garcia-Granero M, Sanchez-Carpintero I, Rabago G, Herreros J. A prospective study of incident nonmelanoma skin cancer in heart transplant recipients. J Invest Dermatol 2000;115:1158-1160.
19. Ong CS, Keogh AM, Kossard S, Macdonald PS, Spratt PM. Skin cancer in Australian heart transplant recipients. J Am Acad Dermatol 1999;40:27-34.
20. Hiesse C, Kriaa F, Rieu P, Larue JR, Benoit G, Bellamy J, et al. Incidence and type of malignancies occurring after renal transplantation in conventionally and cyclosporine-treated recipients: analysis of a 20-year period in 1600 patients. Transplant Proc 1995;27:972-974.
21. Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: Randomised comparison of two cyclosporine regimens. Lancet 1998;351:623-628.
22. Servilla KS, Burnham DK, Daynes RA. Ability of cyclosporine to promote the growth of transplanted ultraviolet radiation-induced tumors in mice. Transplantation 1987;44:291-295.
23. McGregor JM, Berkhout RJM, Rozycka M, Ter Schegget J, Bouwes Bavinck JN, Brooks L, et al. p53 mutations implicate sunlight in post-transplant skin cancer irrespective of human papillomavirus status. Oncogene 1997;15:1737-1740.
24. Otley CC, Coldiron BM, Stasko T, Goldman GD. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants. Arch Dermatol 2001;137:459-463.
25. Sheil AGR. Skin cancer in renal transplant recipients. Transplant Sci 1994;21:42-45.
26. Frezza EE, Fung JJ, van Thiel DH. Non-lymphoid cancer after liver transplantation. Hepatogastroenterology 1997;44:1172-1181.
27. Jonas S, Rayes N, Neumann U, Neuhaus R, Bechstein WO, Guckelberger O, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997;80: 1141-1150.
28. Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg 2001;27:562-564.
29. McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol 1999;140:656-660.
30. Bouwes Bavinck JN, Tieben LM, Van Der Woude FJ, Tegzess AM, Hermans J, Ter Schegget J, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: A double-blind, placebo-controlled study. J Clin Oncol 1995;13:1933-1938.
31. Otley C. Organization of a specialty clinic to optimize the care of organ transplant recipients at risk for skin cancer. Dermatol Surg 2000;26:709-712.